Literature DB >> 26132518

Synthetic Cannabinoids.

Brooke Mills1, Andres Yepes, Kenneth Nugent.   

Abstract

Synthetic cannabinoids (SCBs), also known under the brand names of "Spice," "K2," "herbal incense," "Cloud 9," "Mojo" and many others, are becoming a large public health concern due not only to their increasing use but also to their unpredictable toxicity and abuse potential. There are many types of SCBs, each having a unique binding affinity for cannabinoid receptors. Although both Δ-tetrahydrocannabinol (THC) and SCBs stimulate the same receptors, cannabinoid receptor 1 (CB1) and cannabinoid receptor 2 (CB2), studies have shown that SCBs are associated with higher rates of toxicity and hospital admissions than is natural cannabis. This is likely due to SCBs being direct agonists of the cannabinoid receptors, whereas THC is a partial agonist. Furthermore, the different chemical structures of SCBs found in Spice or K2 may interact in unpredictable ways to elicit previously unknown, and the commercial products may have unknown contaminants. The largest group of users is men in their 20s who participate in polydrug use. The most common reported toxicities with SCB use based on studies using Texas Poison Control records are tachycardia, agitation and irritability, drowsiness, hallucinations, delusions, hypertension, nausea, confusion, dizziness, vertigo and chest pain. Acute kidney injury has also been strongly associated with SCB use. Treatment mostly involves symptom management and supportive care. More research is needed to identify which contaminants are typically found in synthetic marijuana and to understand the interactions between different SBCs to better predict adverse health outcomes.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26132518     DOI: 10.1097/MAJ.0000000000000466

Source DB:  PubMed          Journal:  Am J Med Sci        ISSN: 0002-9629            Impact factor:   2.378


  31 in total

Review 1.  Pharmacology and adverse effects of new psychoactive substances: synthetic cannabinoid receptor agonists.

Authors:  Eun Yong Chung; Hye Jin Cha; Hyun Kyu Min; Jaesuk Yun
Journal:  Arch Pharm Res       Date:  2021-04-02       Impact factor: 4.946

Review 2.  Synthetic Pot: Not Your Grandfather's Marijuana.

Authors:  Benjamin M Ford; Sherrica Tai; William E Fantegrossi; Paul L Prather
Journal:  Trends Pharmacol Sci       Date:  2017-02-02       Impact factor: 14.819

3.  The Importance of Recognizing Cannabinoid Hyperemesis Syndrome from Synthetic Marijuana Use.

Authors:  Xibei Liu; Angela Villamagna; Ji Yoo
Journal:  J Med Toxicol       Date:  2017-03-28

4.  Stroke due to Bonzai use: two patients.

Authors:  Baki Dogan; Hakan Dogru; Levent Gungor; Kemal Balci
Journal:  World J Emerg Med       Date:  2016

5.  Acute myocardial infarction triggered by use of synthetic cannabis.

Authors:  Brooke Mills; Emma Dishner; Carlos E Velasco
Journal:  Proc (Bayl Univ Med Cent)       Date:  2018-03-12

6.  Synthetic Cannabinoids Use in Elderly Patients.

Authors:  Nahla Mahgoub; Robert C Young
Journal:  J Psychiatr Pract       Date:  2017-05       Impact factor: 1.325

7.  Delayed Intracerebral Hemorrhage after Synthetic Cannabis (Bonsai) Abuse; Case Report and Literature Review.

Authors:  Gülçin Aydin; Bülent Bakar
Journal:  Bull Emerg Trauma       Date:  2019-07

8.  Alterations of the hematologic cells in synthetic cannabinoid users.

Authors:  Derya Guzel; Ahmet Bulent Yazici; Esra Yazici; Atila Erol
Journal:  J Clin Lab Anal       Date:  2017-02-07       Impact factor: 2.352

9.  Cannabinoid receptor 2 as a novel target for promotion of renal cell carcinoma prognosis and progression.

Authors:  Jianfeng Wang; Yunze Xu; Liangsong Zhu; Yun Zou; Wen Kong; Baijun Dong; Jiwei Huang; Yonghui Chen; Wei Xue; Yiran Huang; Jin Zhang
Journal:  J Cancer Res Clin Oncol       Date:  2017-10-09       Impact factor: 4.553

Review 10.  Exercise as an adjunctive treatment for cannabis use disorder.

Authors:  Angelique G Brellenthin; Kelli F Koltyn
Journal:  Am J Drug Alcohol Abuse       Date:  2016-06-17       Impact factor: 3.829

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.